"Oct. 17, 2012 -- Extreme agitation, aggressiveness, and psychosis are common among people with Alzheimer's disease -- especially in its later stages -- and they are among the symptoms most often associated with admission to nursing homes."...
Physicians are advised to discuss the following issues with patients for whom they prescribe RISPERDAL® and their caregivers:
Interference With Cognitive And Motor Performance
Inform patients and caregivers that RISPERDAL® has the potential to impair judgment, thinking, or motor skills. Advise caution about operating hazardous machinery, including automobiles, until patients are reasonably certain that RISPERDAL® therapy does not affect them adversely [see WARNINGS AND PRECAUTIONS].
Advise patients and caregivers to notify their physician if the patient becomes pregnant or intends to become pregnant during therapy [see Use In Specific Populations].
Inform patients and caregivers that risperidone and its active metabolite are present in human breast milk; there is a potential for serious adverse reactions from RISPERDAL® in nursing infants. Advise patients that the decision whether to discontinue nursing or to discontinue the RISPERDAL® should take into account the importance of the drug to the patient [see Use in Specific Populations].
Advise patients and caregivers to inform their physicians if the patient is taking, or plans to take, any prescription or over-the-counter drugs, because there is a potential for interactions [see DRUG INTERACTIONS].
Advise patients to avoid alcohol while taking RISPERDAL® [see DRUG INTERACTIONS].
Inform patients with Phenylketonuria and caregivers that RISPERDAL® M-TAB® Orally Disintegrating Tablets contain phenylalanine. Phenylalanine is a component of aspartame. Each 4 mg RISPERDAL® M-TAB® Orally Disintegrating Tablet contains 0.84 mg phenylalanine; each 3 mg RISPERDAL® M-TAB® Orally Disintegrating Tablet contains 0.63 mg phenylalanine; each 2 mg RISPERDAL® M-TAB® Orally Disintegrating Tablet contains 0.42 mg phenylalanine; each 1 mg RISPERDAL® M-TAB® Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL® M-TAB® Orally Disintegrating Tablet contains 0.14 mg phenylalanine [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 5/8/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Risperdal Information
Risperdal - User Reviews
Risperdal User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get tips on therapy and treatment.